Combined Use of Cabozantinib and Nivolumab in Clinical Practice
Introduction. The present article discusses renal cancer, one of the common malignant diseases. Historical and modern therapies are considered, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The results of clinical studies evaluating the efficacy of combined drug therapy are...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2024-04-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. The present article discusses renal cancer, one of the common malignant diseases. Historical and modern therapies are considered, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The results of clinical studies evaluating the efficacy of combined drug therapy are discussed, including the combination of immune checkpoint inhibitors with angiogenesis of targeted therapy.Materials and methods. A case is presented of a patient with metastatic clear cell renal cell carcinoma with multiple lung metastases. The diagnosis was established using computed tomography data and was not verified. Various therapy regimens were used during treatment, including pazopanib, nivolumab, and the combination of nivolumab with cabozantinib.Results and discussion. Follow-up examinations showed disease stabilization and normal tolerance of therapy. Eventually, the patient underwent laparoscopic cytoreductive nephrectomy. The therapy with nivolumab in combination with cabozantinib is still ongoing.Conclusion. The combined use of cabozantinib and nivolumab currently constitutes a promising strategy for treating renal cell cancer, in which cabozantinib prevents tumor progression, and nivolumab increases immune system activity, promoting tumor cell destruction. |
|---|---|
| ISSN: | 2076-3093 2307-0501 |